Dwight JD - Revance Chief Counsel
| RVNCDelisted Stock | USD 3.65 0.00 0.00% |
Executive
Dwight JD is Chief Counsel of Revance
| Age | 49 |
| Phone | 615 724 7755 |
| Web | https://www.revance.com |
Revance Management Efficiency
The company has return on total asset (ROA) of (0.2436) % which means that it has lost $0.2436 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.9678) %, meaning that it created substantial loss on money invested by shareholders. Revance's management efficiency ratios could be used to measure how well Revance manages its routine affairs as well as how well it operates its assets and liabilities.Revance currently holds 478.43 M in liabilities with Debt to Equity (D/E) ratio of 2.94, implying the company greatly relies on financing operations through barrowing. Revance has a current ratio of 3.31, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Revance's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Scott Gangloff | Akero Therapeutics | 51 | |
| Matthew Metivier | Nuvalent | N/A | |
| Lukas MD | Apellis Pharmaceuticals | 53 | |
| Snehal Naik | Ventyx Biosciences | N/A | |
| Amanda Kurihara | 89bio Inc | N/A | |
| Deborah JD | Nuvalent | 49 | |
| JD Esq | Immunocore Holdings | 58 | |
| Thomas Hare | Madrigal Pharmaceuticals | N/A | |
| Benjamin Lane | Nuvalent | N/A | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
| Jonathan JD | Stoke Therapeutics | 34 | |
| MS MD | DiaMedica Therapeutics | 51 | |
| Christina Rossi | Blueprint Medicines Corp | 47 | |
| Jason Hoitt | Stoke Therapeutics | 47 | |
| Mark Underwood | Madrigal Pharmaceuticals | N/A | |
| James Kanter | Terns Pharmaceuticals | N/A | |
| Alex Howarth | Madrigal Pharmaceuticals | 55 | |
| Ambarish Shah | DiaMedica Therapeutics | N/A | |
| Karen Lewis | Apellis Pharmaceuticals | 52 | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Perrin BS | Nuvalent | N/A | |
Management Performance
| Return On Equity | -20.97 | ||||
| Return On Asset | -0.24 |
Revance Leadership Team
Elected by the shareholders, the Revance's board of directors comprises two types of representatives: Revance inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Revance. The board's role is to monitor Revance's management team and ensure that shareholders' interests are well served. Revance's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Revance's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dwight JD, Chief Counsel | ||
| Dustin Sjuts, Vice President of Strategy and Sales | ||
| Conor Gallagher, Head Aesthetics | ||
| Jeanie Herbert, Sr. Director of Investor Relations | ||
| Mark Foley, CEO Director | ||
| Erica Jordan, Chief Officer | ||
| Azita Nejad, VP Operations | ||
| Dwight Moxie, Chief Counsel | ||
| Justin Ford, VP People | ||
| Amie Krause, Chief Officer | ||
| MD MBA, Chief Officer | ||
| Jessica Serra, Head ESG | ||
| Aubrey Rankin, Consultant | ||
| Tobin Schilke, CFO and Principal Financial Officer | ||
| Taryn Conway, Vice President of Marketing |
Revance Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Revance a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -20.97 | ||||
| Return On Asset | -0.24 | ||||
| Profit Margin | (0.72) % | ||||
| Operating Margin | (0.54) % | ||||
| Current Valuation | 680.39 M | ||||
| Shares Outstanding | 104.39 M | ||||
| Shares Owned By Insiders | 8.55 % | ||||
| Shares Owned By Institutions | 87.45 % | ||||
| Number Of Shares Shorted | 4.51 M | ||||
| Price To Earning | (7.60) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Revance Stock
If you are still planning to invest in Revance check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Revance's history and understand the potential risks before investing.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |